Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 ...

Previously known as the Model 2, but more recently referred to as the Model Q, a compact Tesla could sit below £30,000, where it would bring top-notch EV tech, including Tesla’s Supercharger ...

The Zymeworks (NASDAQ:ZYME) story over the last two years was one of transformation and execution. The process started with the out-licensing of Ziihera, the brand name for zanidatamab ...

Stock futures edged lower on Tuesday as investors weighed the possibility of the Fed delivering its final rate cut in 2024, with focus shifting to hints about the central bank's outlook for 2025.